Abstract
In little more than a decade, induced exon skipping as a therapy to treat Duchenne muscular dystrophy (DMD) has progressed from a concept tested in vitro, to pre-clinical evaluation in mouse and dog models, and recent completion of Phase I clinical trials in man. There is no longer any doubt that antisense oligomers can redirect dystrophin gene processing and by-pass protein truncating mutations after direct injection into muscle. Proof-of-concept has been demonstrated in human dystrophic muscle, with trials in Leiden and London showing that two different oligomer chemistries can restore the reading-frame in selected DMD patients by excising dystrophin exon 51. Systemic delivery of both oligomer types into DMD patients has commenced with promising results but it remains to be established if this therapy will have measurable clinical benefits. Targeted removal of exon 51 will only be directly applicable to about one in ten DMD individuals, and the immediate challenges include development of appropriate and effective delivery regimens, and extending spliceswitching therapies to other dystrophin gene lesions. The success of induced exon skipping has spawned a number of “fusion therapies”, including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues. This review summarizes the pivotal events leading to the completion of the first proof-of-concept trials and speculates on some of the scientific, ethical, regulatory and commercial challenges facing targeted exon skipping for the treatment of DMD.
Keywords: Duchenne muscular dystrophy, Becker muscular dystrophy, Dystrophin, Antisense oligomer, Exon skipping, Molecular medicine
Current Pharmaceutical Design
Title: Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy
Volume: 16 Issue: 8
Author(s): Steve. D. Wilton and Susan Fletcher
Affiliation:
Keywords: Duchenne muscular dystrophy, Becker muscular dystrophy, Dystrophin, Antisense oligomer, Exon skipping, Molecular medicine
Abstract: In little more than a decade, induced exon skipping as a therapy to treat Duchenne muscular dystrophy (DMD) has progressed from a concept tested in vitro, to pre-clinical evaluation in mouse and dog models, and recent completion of Phase I clinical trials in man. There is no longer any doubt that antisense oligomers can redirect dystrophin gene processing and by-pass protein truncating mutations after direct injection into muscle. Proof-of-concept has been demonstrated in human dystrophic muscle, with trials in Leiden and London showing that two different oligomer chemistries can restore the reading-frame in selected DMD patients by excising dystrophin exon 51. Systemic delivery of both oligomer types into DMD patients has commenced with promising results but it remains to be established if this therapy will have measurable clinical benefits. Targeted removal of exon 51 will only be directly applicable to about one in ten DMD individuals, and the immediate challenges include development of appropriate and effective delivery regimens, and extending spliceswitching therapies to other dystrophin gene lesions. The success of induced exon skipping has spawned a number of “fusion therapies”, including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues. This review summarizes the pivotal events leading to the completion of the first proof-of-concept trials and speculates on some of the scientific, ethical, regulatory and commercial challenges facing targeted exon skipping for the treatment of DMD.
Export Options
About this article
Cite this article as:
Wilton D. Steve. and Fletcher Susan, Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy, Current Pharmaceutical Design 2010; 16 (8) . https://dx.doi.org/10.2174/138161210790883480
DOI https://dx.doi.org/10.2174/138161210790883480 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Texture Spectrum Coupled with Entropy and Homogeneity Image Features for Myocardium Muscle Characterization
Current Bioinformatics Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience